Long Island Jewish Medical Center Appoints Mathew Foley MD Medical Director

Long Island Jewish (LIJ) Medical Center has appointed Mathew Foley MD, as its medical director. Dr. Foley succeeds Richard Schwarz, MD, who is taking on the new role of vice president of medical affairs and quality at Northwell Health.

Dr. Foley is an experienced clinical leader; he previously served as vice chair of emergency medicine at North Shore University Medical Center in Manhasset. Prior to joining Northwell, Dr. Foley spent stints in emergency medicine at NYU Langone and University Hospital of Brooklyn at SUNY Downstate.

Dr. Foley was vice chair of emergency medicine and an associate professor at NYU Langone Health, where he had emergency department oversight for NYU Tisch, NYU Brooklyn, NYU Orthopedic Hospital, Bellevue Hospital and NYU Cobble Hill. Dr. Foley also led the creation of NYU Langone’s telemedicine program.

“Dr. Foley is an accomplished and respected emergency medicine physician with a wealth of experience,” said Michael Gitman, MD, executive director, LIJ Medical Center. “He is a collaborative, innovative leader and the perfect choice to succeed Dr. Richard Schwarz, who has been promoted to vice president of medical affairs and quality for Northwell Health. We welcome Dr. Foley and wish Dr. Schwarz well.”

Dr. Schwarz will play an integral role leading Northwell’s policies and procedures while co-chairing the health system’s performance improvement coordinating group. Dr. Schwarz previously held leadership posts at Huntington Hospital, Stony Brook University Hospital as well as several dialysis and medical groups throughout the region.

Both Drs. Schwarz and Foley proved to be crucial clinical leaders during COVID-19, especially during the First Wave when their respective hospitals stood at the epicenter of the pandemic. Dr. Foley was named Physician of the Year at North Shore University Hospital in 2020-21.

“I am honored to join Long Island Jewish Medical Center, which serves one of the most diverse populations in the nation,” said Dr. Foley. “I am grateful for the opportunity to support the staff of every department at LIJ to help create destination programs. Fostering the best working environment within our medical center is paramount to LIJ’s mission of providing quality care for all patients regardless of income, race, religion, sexuality or creed.”

Dr. Foley received his medical degree from George Washington University in Washington, D.C., earned a Master of Science in nutrition from Columbia University in New York as well as a Bachelor of Arts in human biology from Stanford University in Palo Alto, Calif.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”